Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Biomarker testing is an important part of precision medicine; however, many commercial health plans and state Medicaid programs lack adequate coverage, which can have life-threatening consequences for patients with cancer who could benefit from biomarker testing.
Some good news: health insurance coverage advocates have seen “wins” in three states in 2021: California, Illinois, and Louisiana. In this episode, we spoke with two healthcare advocates who explore these recent policy changes as it relates to biomarker testing. Tune in to find out what these legislative changes mean for your program or practice—and discover approaches to advise policymakers in your state on biomarker testing.
To learn more about this education program, please visit the BiomarkerLIVE webpage. This project is supported by AbbVie, AstraZeneca, Lilly Oncology, and Merck & Co., Inc. Phase one of this project was supported by Bristol Myers Squibb.